People with prediabetes often develop diabetes, but many of them also manage to return to normoglycemia. What determines these different trajectories? And can we identify biomarkers that predict the different developments of prediabetes? To answer these questions, researchers from the Paul Langerhans Institute Dresden of the German Center for Diabetes Research (DZD), together with other experts, used the multicenter DZD study PLIS (Prediabetes Lifestyle Intervention Study). The researchers compared the proteome and metabolome signatures of prediabetes patients who showed opposite disease progressions, i.e. they focused on patients who either developed diabetes or whose blood glucose levels returned to normal over time. The results of this work have now been published in the journal Diabetes Care.

The progression of prediabetes to type 2 diabetes is associated with pancreatic beta cell dysfunction, while remission to normoglycemia is thought to be related to an improvement in insulin sensitivity. In order to understand the mechanisms and identify potential biomarkers for the possible further course of prediabetes, the researchers conducted an exploratory case-control study with participants of the PLIS study, comparing the proteomic and metabolomic profile of individuals with prediabetes who developed diabetes within one year with that of individuals who returned to normoglycemia.

The team, led by Prof Nikolaos Perakakis, analyzed 1389 proteins and 152 metabolites from plasma samples of individuals at the prediabetes stage and one year later, when some of the subjects had returned to normoglycemia while others developed diabetes. Significant differences were found in 14 proteins in new-onset diabetes compared to normoglycemia, with six of these proteins observed for the first time in this context. Elevated levels of two of the proteins, dicarbonyl/L-xylulose reductase (DCXR) and glutathione S-transferase A3 (GSTA3), at the prediabetes stage were associated with a significantly increased risk of developing diabetes one year later.

Another aspect of the study highlighted the role of inflammatory and immune system pathways in glucose homeostasis. Here, the scientists were able to show that signaling pathways related to leukocyte chemotaxis, chemokines, cytokine interactions and immune responses to infections can be associated with the progression from prediabetes to diabetes.

Metabolomic signatures in new-onset diabetes were characterized by increased levels of intermediate density lipoproteins, branched-chain amino acids, apolipoprotein A2 and glutamate. Metabolomic and proteomic signatures distinguishing between prediabetes trajectories correlated more strongly with markers of insulin sensitivity and to a lesser extent with markers of beta cell function.

“We were able to successfully identify new candidates that are associated with the progression from prediabetes to diabetes or its remission. At the same time, we were able to show that signaling pathways that regulate immune responses are strongly associated with prediabetes progression,” summarizes Prof Perakakis. “In the future, the new candidate proteins could serve as biomarkers for prediabetes progression or as targets for evaluating their role in glucose homeostasis in mechanistic studies.”

Original publication: Barovic, M., Hahn, JJ., Heinrich, A. et al. Proteomic and Metabolomic Signatures in Prediabetes Progressing to Diabetes or Reversing to Normoglycemia Within 1 Year. Diabetes Care. 2025 Mar 1;48(3):405-415.

Source: DZD

A recently launched study under the auspices of DZNE is investigating whether patients with “dementia of unclear etiology” benefit from examination of their brains using amyloid positron emission tomography (amyloid PET). Should this form of diagnostics contribute significantly to a better disease progression, the statutory health insurance providers could possibly pay for such brain scans in the future. The study was commissioned by the Federal Joint Committee (G-BA), the body that decides on the services covered by German statutory health insurers.

Every year, more than 350,000 people in Germany develop dementia. Whether this is due to Alzheimer’s or another neurological disease often remains unclear. “Diagnostic uncertainty prevents the best possible treatment. Although there is currently no cure for dementia, there are specific therapeutic measures depending on the form of dementia that support the capacity to independently manage activities of daily living. This is important for the quality of life of patients,” explains Prof. Stefan Teipel, dementia researcher at the DZNE’s Rostock/Greifswald site and head of the Section for Gerontopsychosomatics and Dementia at Rostock University Medical Center. “With this in mind, we investigate whether amyloid PET can help provide good care for people with dementia.”

Study on behalf of the G-BA

Amyloid PET can detect so-called amyloid in the brain. These protein deposits are hallmarks of Alzheimer’s and thus provide important evidence for diagnosis. It was shown that this technique increases diagnostic certainty. But does it provide added value for patients? In fact, such benefit has not been clearly demonstrated so far, which is why this examination is generally not covered by statutory health insurance providers in Germany. The current research project named “ENABLE: Patient- and care-related benefits of amyloid PET imaging” (a study according to §137e of the German Social Code Book V) aims to provide certainty. The criterion is how the study participants’ everyday skills develop as a consequence of PET examination and subsequent therapy. The project is financed by the “Federal Joint Committee”, a central body in the German healthcare system. “Our study results will be considered in future decisions on the services provided by statutory health insurance companies,” says study leader Stefan Teipel.

First participants enrolled

Under the lead of DZNE, more than 20 study centers across Germany located at university hospitals as well as institutions from the private practice sector will participate in the investigation. “After several years of preparation, we have now enrolled the first subjects in the study. By 2026, we aim to include more than a thousand individuals with mild to moderate dementia of unclear cause, all of whom being treated within the framework of regular care,” says Teipel.

Prof. Gabor Petzold, DZNE’s Director of Clinical Research, sees this study as a prime example of cooperation between research and clinical practice: “Partners from academia, industry and healthcare are involved in this project. This way, we are building a bridge between research and practice. This study will provide important momentum for the health care of people with dementia in Germany.”

Assessing everyday functioning

The study participants will be randomly assigned to two equally sized groups: The subjects in one group will be examined with amyloid PET, while the others will not. This will only include patients in whom the alternative procedure for detecting amyloid (which involves taking a fluid sample from the spinal canal) could not be performed or did not provide a conclusive result. “The PET findings will have an impact on medication and other therapeutic measures. The question now is whether this has measurable consequences. That is, if these people are better able to cope with everyday life than those in the control group who did not have a PET scan,” says Teipel. “That is why we will monitor the development of the daily living skills of all study participants over a period of 24 months.”

Source: DZNE

The VADYS-ME research project is investigating how vascular problems and circulatory disorders could trigger symptoms such as extreme fatigue and concentration problems in patients with ME/CFS - with the aim of developing better diagnostic and therapeutic options.

The aim of the project is to better understand the causes and mechanisms of this debilitating disease and to develop new approaches for diagnosis and treatment. The project is headed by Prof. Wolfram Döhner, MD, scientist at the Berlin Institute of Health (BIH) and the German Heart Centre at Charité - Universitätsmedizin Berlin, partner of the German Centre for Cardiovascular Research (DZHK).

ME/CFS: vascular problems as a key mechanism?

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) leads to a severe reduction in physical and mental performance. Those affected often suffer from extreme exhaustion, muscle weakness and concentration problems. The disease occurs after infectious diseases, and a significant increase in frequency has been observed, particularly after the COVID pandemic. Other viral diseases such as the Epstein-Barr virus (EBV), which is responsible for glandular fever, as well as influenza or other respiratory infections are also associated with the development of ME/CFS.

This joint project, VADYS-ME, is investigating whether and how disturbances in the regulation of the blood vessels and blood supply affect the metabolism and thus the function of tissues and organs. This in turn can contribute to typical symptoms such as muscular weakness, generalised fatigue and concentration disorders.

Innovative approaches: Imaging, biomarkers and data analysis

Imaging techniques such as magnetic resonance imaging are used to analyse how well the brain, heart and muscles are supplied with blood. The metabolism of the skeletal muscles is also analysed and blood samples from ME/CFS patients are examined specifically for certain characteristics (‘biomarkers’) of the regulation of blood flow.

The VADYS-ME research project is being carried out by Charité in cooperation with the Technical University of Munich (project leader Prof Dr Schmaderer) and is being funded by the Federal Ministry of Education and Research (BMBF) with 2.6 million euros. It brings together the expertise of five research teams from Charité, including the Berlin Institute of Health (BCRT), the German Heart Centre Berlin, the Department of Neurology at Charité and the Experimental and Clinical Research Center (ECRC), as well as the Technical University of Munich.  Patient organisations (Lost Voices Foundation and the ME/CFS Research Foundation) have also been involved in the project from the outset in order to incorporate the perspective of patients and sufferers into the clinical research work.

Professor Wolfram Döhner, MD, who is leading the project, explains: ‘With VADYS-ME, we want to better understand the mechanisms of ME/CFS and look for new methods to make a reliable and rapid diagnosis and also open up opportunities for new treatments to ultimately improve patients’ quality of life.’

Source: DZHK

The interdisciplinary project DEFENDER is developing innovative approaches to combat (re-)emerging viruses. The project, coordinated by the Leibniz Institute of Virology (LIV), is being funded with around 9.6 million euros as part of Horizon Europe. Almost 700,000 euros of these will go to Prof. Mark Brönstrup, a researcher at the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF).

The COVID-19 pandemic has highlighted the immense risk potential posed by (re‑)emerging viruses. There are neither approved vaccines nor specific therapies for many of these viruses. This is precisely where DEFENDER (iDEntification oF novel viral Entry factors aNd DevelopmEnt of antiviRal approaches) comes in: The project aims to develop new, alternative antiviral approaches in order to be prepared for future outbreaks.

Unique research approach

By using state-of-the-art technologies such as CRISPR gene technology, bioinformatic analyses and artificial intelligence, DEFENDER is pursuing an integrated concept for the development of new targets for antiviral therapies that focuses on both the host and the virus. On the host side, new host factors are identified that play a key role in viral entry, while on the virus side, virus structures are identified that represent potential targets for therapeutic antibodies or nanobodies.

The research focus of the DEFENDER consortium lies on highly pathogenic viruses such as the Nipah and Lassa viruses as well as viruses transmitted by mosquitoes that cause Zika, dengue, yellow fever and chikungunya.

Strengthening European pandemic preparedness

Starting on January 1, 2025, DEFENDER will run for five years and will make a decisive contribution to improving European and global pandemic preparedness. Systematic research into virus-host interactions will be used to develop antiviral candidates that can be followed up in clinical trials.

Project leader Prof.  Stephanie Pfänder (Research Group Emerging Viruses, LIV) emphasises: “DEFENDER combines the expertise of leading European research institutions in the fields of virology, structural biology, genetics and bioinformatics to develop innovative, forward-looking antiviral strategies.We are convinced that we will make a significant contribution to combating future virus outbreaks.“

Prof. Mark Brönstrup, head of the Department “Chemical Biology” at the HZI and scientist in the Novel Antibiotics research area of the DZIF, adds: “We are happy to contribute our expertise in antiviral drug conjugates such as PROTACs to DEFENDER to validate new therapeutic concepts against emerging pathogens.”

In addition to the LIV and the HZI, ten other institutions are involved in DEFENDER: The University of Zurich (Switzerland), Greifswald University Medicine (Germany), Universität zu Lübeck (Germany), École Polytechnique Fédérale de Lausanne (Switzerland), Heidelberg University (Germany), Liverpool School of Tropical Medicine (England), Institut Pasteur (Paris, France), Ruhr University Bochum (Germany), Phillips-Universität Marburg (Germany) and the Bernhard Nocht Institute for Tropical Medicine (Hamburg, Germany).

Source: DZIF

The DZPG researches mental health in the context of the ecological crisis - Climate change leads to psychological stress. There are several reasons for this: Firstly, there is the fear of an uncertain future with considerable uncertainties, loss of prosperity and distribution struggles. Secondly, more and more people are personally affected by extreme weather events such as those in the Ahr Valley. Thirdly, environmental problems such as increasing heat and air pollution are affecting people not only physically but also emotionally. DZPG spokespersons Professor Andreas Heinz and Professor Andreas Meyer-Lindenberg name ways out: the DZPG wants to better research the interaction between the environment and mental health and develop new treatment and prevention approaches on this basis.

Research into the psychological effects of environmental problems is far from starting from scratch. We know that “natural disasters are associated with an increase in depression, anxiety and trauma-related disorders,” says DZPG spokesperson Meyer-Lindenberg. This increase can be observed above all in areas where many people are directly affected by a disaster such as flooding, such as recently in the Ahr valley, Saarland or Bavaria, but also beyond. This has been well researched in the aftermath of Hurricane Katrina, for example.

In addition to trauma-related disorders, there are indirect consequences of climate change such as food shortages, economic crises, violent conflicts and involuntary migration. These are also psychological risk and stress factors that can lead to uncertainty and anxiety before they occur and to trauma afterwards.

Global warming, plastic, overfishing: retreating from the mass of problems is becoming more difficult

In addition to these two factors, the consequences of the current ecological crisis are compounded by grief over the loss of an intact environment (“solastalgia”) and fear of an uncertain future, also known as “climate anxiety”. DZPG spokesperson Andreas Heinz explains: “Humanity is not only faced with the problem of global warming and its consequences. There is also the loss of biodiversity, the plastic crisis in the oceans, overfishing, over-fertilization of the soil and the poor condition of the forests. No matter where we look: They see the destruction of habitats that in the past could offer carefree experiences of nature. This makes it difficult to relax and puts a strain on the soul, and this is where we at the DZPG must continue our research: What increases resilience? Who is particularly at risk?” Without prevention and effective tools against the psychological consequences of environmental degradation, there is a risk of considerable economic damage due to mental illness.

There are also still questions regarding care. “Even if symptoms such as anxiety disorders are often easily treatable: The basic problem, the state of the environment, is not a traumatic experience in the past, but a rational concern,” explains Andreas Heinz. Because unlike a violent childhood, for example, which those affected can leave behind, the destruction of the environment does not stop; spatial or temporal distance are not available as therapeutic aids.

Ecological handprint can increase resilience

However, you are not at the mercy of your feelings even today, says Meyer-Lindenberg. One way can be to increase your own “ecological handprint” and become aware of your scope for action. “Meaningful work or voluntary work that counteracts the environmental crisis and a way of life that doesn't ignore the problems of the present can be an effective step against despair.” Although the environmental crisis cannot be solved single-handedly, trying to counteract the environmental crisis with your own behavior and energy can increase your own mental resilience.

One Mental Health Hub

The WHO's One Health approach examines the connections between humans, animals, plants and their shared environment. While this currently focuses on physical health, the DZPG is extending this concept to mental health and will conduct better research into the interaction with the environment and develop new treatment and prevention approaches on this basis. The linchpin of the research activities is the One Mental Health Hub, which is scheduled to be founded in 2025.

Source: DZPG

A nationwide research consortium led by the University Hospital Schleswig-Holstein (UKSH) and the Medical Faculty of the Christian-Albrechts-University of Kiel (CAU) has received €4.9 million in funding for the COVIDOM+ study. The aim is to investigate the long-term effects of a SARS-CoV-2 infection, particularly Post-COVID Syndrome (PCS), in comparison to other respiratory diseases.

The involved institutions are part of the Airway Research Center North (ARCN) of the German Center for Lung Research (DZL). In collaboration with the University Hospital Würzburg and Charité – Universitätsmedizin Berlin, participants from various regions of Germany – including Schleswig-Holstein, Bavaria, and Berlin – will be followed over several years to analyze the long-term effects of COVID-19, especially PCS.

Focus on Long-Term Effects of COVID-19

The COVIDOM+ study builds on the ongoing COVIDOM cohort since 2020 and investigates how frequently and severely PCS occurs and how it differs from other post-infectious diseases such as ME/CFS. Typical symptoms like chronic fatigue, concentration difficulties ("brain fog"), or breathing problems will be analyzed. The psychological and potentially age-related effects of COVID-19 are also in focus.

“The follow-up study COVIDOM+ will help us better understand the frequency, severity, and long-term effects of Post-COVID Syndrome. We aim to determine how factors such as the timing of infection, vaccination status, disease course, and pre-existing conditions influence the development of PCS and identify different manifestations, known as phenotypes, while distinguishing them from other post-infectious diseases like chronic fatigue syndrome,” explains Prof. Dr. Jan Heyckendorf, DZL scientist, Director of the Department of Internal Medicine I at UKSH, Campus Kiel, and project leader of COVIDOM+. “The insights gained will contribute to the development of clinical guidelines and improve the care of affected individuals through more precise diagnostic and treatment approaches,” adds PD Dr. Thomas Bahmer, also a DZL scientist and co-study leader of COVIDOM+.

Funding and Outlook

COVIDOM+ is funded by the Federal Ministry of Health (BMG) with €4.9 million for the years 2025 and 2026. The results aim to improve the care of patients with Post-COVID Syndrome and other long-term effects.

Source: DZL

A groundbreaking study by scientists at the LMU Hospital Munich and the German Centre for Cardiovascular Research has shown that antibodies and the complement system play central roles in the development of thrombosis. This discovery could lead to new treatment strategies that do not involve the bleeding risk of conventional anticoagulants.

Venous thromboembolism (VTE) is a life-threatening blood clot which its frequency is increasing worldwide despite preventive measures. The role of antibodies in immune defence has long been known, but this study brings surprising new findings: IgM and IgG antibodies, regardless of their specificity to a particular antigen, promote the formation of blood clots.

Antibodies as the key to thrombosis formation

IgM antibodies bind to endothelial cells that line the blood vessels and activate them, which triggers the accumulation of platelets. This phase is the first step in the formation of a thrombus. IgG antibodies then attach to activated platelets and trigger the complement system, which initiates a cascade of biochemical processes that intensify thrombosis formation through inflammatory processes.

‘Our study shows that antibodies and the complement system play a previously underestimated role in the development of thrombosis, regardless of which antigens the antibodies recognise,’ explains Prof. Konstantin Stark, Senior Consultant in Cardiology at the LMU Hospital in Munich and author of the study.

IgM and IgG - more than just defence players

IgM and IgG are reffered to as two of the most important antibodies in the human immune system. IgM antibodies are the first to be produced after an infection and play a decisive role in the initial defence against pathogens. They are particularly efficient in neutralising bacteria and viruses and in activating the complement system. IgG antibodies are the most abundant antibodies in the blood and are responsible for long-term immunity. They mark pathogens so that they can be more easily recognised and eliminated by immune cells.

However, the present study showed that these antibodies not only contribute to immune defence, but can also trigger and promote thrombosis. It is particularly noteworthy that this process occurs independently of the antigen specificity of the antibodies, which means that the antibodies exert their prothrombotic effects without having to recognise a specific antigen.

New therapeutic approaches: Protection against thrombosis without the risk of bleeding

One of the most important discoveries of the study shows that the targeted inhibition of the complement system can prevent thromboses. In contrast to conventional blood thinners, which often increase the risk of severe bleeding, natural blood clotting remains unaffected. The researchers found that this blockade is not only safer, but also effectively reduces thrombosis.

‘This method offers a promising new approach to prevention of thrombosis, which prevents the formation of blood clots without increasing the risk of bleeding,’ explains Prof Stark.

Relevance to COVID-19 and other diseases

The study results not only have an impact on the treatment of venous thrombosis, but also affect other diseases in which the complement system is involved.The parallels between thrombosis development and the thrombotic complications observed in severe COVID-19 cases are of particular scientific interest. In the autopsy samples from COVID-19 patients, the researchers found the same prothrombotic mechanisms as in their animal models: Antibodies and the complement system worked together to promote the formation of blood clots.

These findings could also play a role in the treatment of other immune-mediated thromboses, such as antiphospholipid syndrome. In addition, inhibition of the complement system could play a key role in the future in the treatment of thrombotic complications triggered by vaccines or antibody therapies, as it has been reported regarding COVID-19 vaccines.

Clinical application and future prospects

The possibility of specifically inhibiting the complement system without increasing the risk of bleeding could be particularly important for patients who have a high risk of both thrombosis and bleeding.

‘We are still at the beginning of clinical research of these new therapeutic approaches, but our results offer a promising perspective in the prevention of thrombosis,’ concludes Prof Stark. ‘Our research shows that we can pursue new approaches that primarily target the immune response in order to effectively and safely prevent thrombosis.’

Original publication: Antibodies and complement are key drivers of thrombosis. Stark, K., Kilani, B., Stockhausen, S. et al. Immunity. 2024 Sep 10;57(9):2140-2156.e10.

Source: DZHK

Researchers from Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have identified a mechanism that may explain the neurological symptoms of Long COVID. The study shows that the SARS-CoV-2 spike protein remains in the brain’s protective layers, the meninges, and the skull’s bone marrow for up to four years after infection. This persistent presence of the spike protein could trigger chronic inflammation in affected individuals and increase the risk of neurodegenerative diseases. The team, led by Prof. Ali Ertürk, Director at the Institute for Intelligent Biotechnologies at Helmholtz Munich, also found that mRNA COVID-19 vaccines significantly reduce the accumulation of the spike protein in the brain. However, the persistence of spike protein after infection in the skull and meninges offers a target for new therapeutic strategies.

Spike Protein Accumulates in the Brain

A novel AI-powered imaging technique developed by Prof. Ali Ertürk’s team provides new insights into how the SARS-CoV-2 spike protein affects the brain. The method renders organs and tissue samples transparent, enabling the three-dimensional visualization of cellular structures, metabolites, and, in this case, viral proteins. Using this technology, the researchers uncovered previously undetectable distributions of spike protein in tissue samples from COVID-19 patients and mice.

The study, published in the journal Cell Host & Microbe, revealed significantly elevated concentrations of spike protein in the skull’s bone marrow and meninges, even years after infection. The spike protein binds to so-called ACE2 receptors, which are particularly abundant in these regions. “This may make these tissues especially vulnerable to the long-term accumulation of spike protein,” explains Dr. Zhouyi Rong, the study’s first author. Ertürk adds, “Our data also suggest that persistent spike protein at the brain’s borders may contribute to the long-term neurological effects of COVID-19 and Long COVID. This includes accelerated brain aging, potentially leading to a loss of five to ten years of healthy brain function in affected individuals.”

Vaccines Reduce Spike Protein Accumulation and Brain Inflammation

The Ertürk team discovered that the BioNTech/Pfizer mRNA COVID-19 vaccine significantly reduces the accumulation of spike protein in the brain. Other mRNA vaccines or vaccine types, such as vector- or protein-based vaccines, were not investigated. Mice vaccinated with the mRNA vaccine showed lower levels of spike protein in both brain tissue and the skull’s bone marrow compared to unvaccinated mice. However, the reduction was only around 50%, leaving residual spike protein that continues to pose a toxic risk to the brain. “This reduction is an important step,” says Prof. Ertürk. “Our results, while derived from mouse models and only partially transferable to humans, point to the need for additional therapies and interventions to fully address the long-term burdens caused by SARS-CoV-2 infections.” Furthermore, additional studies are needed to evaluate the relevance of these findings for Long COVID patients.

Long COVID: A Societal and Medical Challenge

Globally, 50 to 60 percent of the population has been infected with COVID-19, with five to ten percent experiencing Long COVID. This sums up to approximately 400 million individuals who may carry significant amounts of spike protein. “This is not just an individual health issue – it is a societal challenge,” says Prof. Ertürk. “Our study shows that mRNA vaccines significantly reduce the risk of long-term neurological consequences and offer crucial protection. However, infections can still occur post-vaccination, leading to persistent spike proteins in the body. These can result in chronic brain inflammation and an increased risk of strokes and other brain injuries, which could have substantial implications for global public health and healthcare systems worldwide."

Advances in Diagnosis and Treatment

“Our findings open new possibilities for diagnosing and treating the long-term neurological effects of COVID-19,” says Ertürk. Unlike brain tissue, the skull’s bone marrow and meninges – areas prone to spike protein accumulation – are more accessible for medical examinations. Combined with protein panels – tests designed to detect specific proteins in tissue samples – this could allow for the identification of spike proteins or inflammatory markers in blood plasma or cerebrospinal fluid. “Such markers are critical for the early diagnosis of COVID-19-related neurological complications,” Ertürk explains. “Additionally, characterizing these proteins may support the development of targeted therapies and biomarkers to better treat or even prevent neurological impairments caused by COVID-19.”

Highlighting the broader impact of the study, leading Helmholtz Munich and Technical University of Munich virologist Prof. Ulrike Protzer adds: “Given the ongoing global impact of COVID-19 and the increasing focus on long-term effects, this study, which sheds light on brain invasion pathways and unexpected long-term host involvement, is timely. These critical insights are not only scientifically significant but also of great interest to society.”

Original publication: Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19. Rong, Z., Mai, H., Ebert, G. et al. 2024. Cell Host & Microbe.

Source: Helmholtz Munich

Special mutations in important protective proteins lead to the proteins being broken down longer and therefore faster. This results in an increased risk of tumor growth. These findings offer new approaches for cancer therapies.

Cancer researchers from the Faculty of Medicine at the University of Freiburg have discovered that certain “non-stop mutations” make important protective proteins against cancer in the body longer, making them “water-shy”. The proteins then become more unstable in the aqueous environment of the cell, are broken down more quickly and can ultimately no longer act effectively against uncontrolled cell growth. This can increase the risk of tumors. The results of the study, which were published in the journal Nature Communications on October 25, 2024, could increase precision in the selection of suitable cancer therapies.

“We were able to show that so-called non-stop mutations can play a major role in the development of cancer. Until now, these changes have been overlooked because they do not affect the basic structure of important proteins,” says study leader Prof Dr Sven Diederichs, who heads the Department of Oncological Research in the Department of Thoracic Surgery at the Freiburg University Medical Center and is a scientist at the Freiburg partner site of the German Consortium for Translational Cancer Research (DKTK). “These findings now offer the possibility of integrating these mutations into cancer treatment decisions,” said Diederichs.

Weakened proteins promote tumor growth

Proteins are important building blocks in our cells and are produced as a chain of molecules according to the blueprint in our genome. The end of such a blueprint is normally formed by a stop signal that ends the sequence of protein building blocks. In the case of a non-stop mutation, this stop signal is lost, so that the protein becomes longer than necessary.

Diederichs' research team has now analyzed 2,335 cases in which these non-stop mutations occurred in various types of cancer in a high-throughput screening. Using a technique called “flow cytometry”, they measured how high the concentration of the extra-long proteins was in the cells. It turned out that more than half of these proteins were degraded before they could do their job.

“We were able to show that the proteins in which the elongation makes them more water-repellent, one could also say water-shy, are more unstable in the aqueous environment of the cell. As a result, they are quickly disposed of by the cell's cleaning system. This means they can no longer fulfill their function,” explains Diederichs.

Tumor suppressor genes and the resulting proteins were particularly affected. These normally prevent the growth of tumors. “These proteins are like the safety brakes in our cells. They ensure that cells only divide when they need to and stop growth if something goes wrong. If these proteins do not function properly, cells can grow uncontrollably and develop into tumors,” says Diederichs.

In the next step, the Freiburg researchers want to further investigate the mechanisms behind the mutations, which have been largely overlooked to date. “On the one hand, we want to understand in more detail how the individual mutations work. On the other hand, we want to test whether the targeted stabilization of the affected proteins could be a basis for new therapeutic approaches,” hopes Diederichs.

Original publication: Suppressive cancer nonstop extension mutations increase C-terminal hydrophobicity and disrupt evolutionarily conserved amino acid patterns. Ghosh, A., Riester, M., Pal, J. et al.  Nat Commun 15, 9209 (2024).

Source: DKTK

The intestinal microbiome is currently the subject of intensive research, as it is of great importance for human health. Intestinal bacteria play an essential role in the defence against dangerous pathogens, which is one of the reasons why the majority of them are among the good guys. On the other hand, some of our lodgers are more prevalent in specific diseases—for whatever reason. This also applies to the widespread but little-researched bacterium Segatella copri. The research group led by Prof Till Strowig at the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF) wanted to determine what makes this bacterium tick. How does it adapt to its environment? And what signals does it react to?

The intestinal microbiome is a highly complex ecosystem with thousands of different types of bacteria. Live and let live, that is the motto. Harmonious coexistence is based on the fact that intestinal bacteria occupy different niches and communicate with each other.

When does Segatella gain the upper hand?

The composition of the human gut microbiome is not always the same. There are significant differences between people in different regions of the world; in the western, highly industrialised world, for example, different bacteria predominate than in developing countries. On the other hand, the gut microbiome varies from person to person in terms of the bacterial species represented and their colonisation density. Despite these differences, there are basic patterns of intestinal colonisation in which a particular key bacterium dominates. Segatella copri is the most prominent germ in one of these three so-called enterotypes. This intestinal bacterium is widespread in developing and emerging countries.

Despite its worldwide distribution, little research has been done on Segatella copri to date. What is known is that the bacterium specialises in the breakdown of dietary fibre. However, what role does it play concerning human health needs to be clarified: is it beneficial, or, on the contrary, does it have adverse effects? Despite the wealth of data on the microbiome, studies to date have not provided an answer to this question.

Clarifying the health significance of Segatella copri is one of the goals of the research work of Prof Till Strowig, head of the "Microbial Immune Regulation" department at the HZI and group leader in the DZIF research areas “Community-Acquired Infections at Mucosal Interfaces” and „Healthcare-Associated Infections”. Cultivating Segatella in the laboratory is difficult, but Strowig's team has succeeded. "We wanted to find out under which conditions increased colonisation with Segatella copri occurs and which processes take place in the cells. To do this, we need insights into how these bacteria work," says Till Strowig.  

Small snippet with a big impact

The programme for all life processes is encoded in the genes, and this is no different in bacteria than in humans. When Segatella copri multiplies and spreads, complex metabolic processes are set in motion. To do this, the relevant genes have to be transcribed. For this transcription, the genetic information is transcribed from DNA (deoxyribonucleic acid) to RNA (ribonucleic acid). We can determine which genes are currently active by examining the so-called transcriptome. This is the entirety of all transcribed RNA molecules in a cell at any given time. "While studying the transcriptome of Segatella copri, we came across a tiny snippet of RNA that plays an essential role in the reproduction and spread of the bacterium," reports first author Dr Youssef El-Mouali. The small piece of RNA—small RNA, to use the technical term—is significantly involved when Segatella copri breaks new ground. The researchers showed this in mice with a defined gut microbiome. The fact that "small RNAs" act as essential control elements in regulating cellular processes is also known from other living organisms, including humans.

Intestinal bacteria communicate with each other

The researchers named the RNA snippet discovered in Segatella copri SrcF (Segatella RNA colonisation factor) and took a closer look at it. They wanted to clarify the question: When is SrcF expressed in the cells? The assumption is that the multiplication of the bacterium is dependent on the food supply. If there is a high supply of dietary fibre, from which S. copri obtains energy, the bacteria will spread and conquer new habitats. The researchers were able to show that certain complex carbohydrates trigger the formation of SrcF. In contrast, a high concentration of fructans—polysaccharides consisting mainly of fruit sugar (fructose)—suppresses SrcF activity.

The researchers also discovered something else: The microbiome's composition influences whether Segatella copri activates the signalling pathway via SrcF. The many different bacterial species that live in peaceful coexistence in the gut compete for available resources and communicate with each other. This is the only way to explain the balanced state of the microbiome: The individual composition of the intestinal microbiome is surprisingly constant, and even after temporary turbulence, the old balance within this ecosystem is usually restored.

"According to our research results, the breakdown of large amounts of fructans appears to influence communication between different intestinal bacteria," says Till Strowig. “We will continue our research in this direction and hope that the better understanding of the gut microbiome that we want to contribute to will eventually be used specifically with a view to human health.”

Original publication: The RNA landscape of the human commensal Segatella copri reveals a small RNA essential for gut colonization. El Mouali, Y., Tawk, C., Huang, K.D. et al. Cell Host Microbe. Sept 2024.

Source: Press release of the Helmholtz Centre for Infection Research

The German Centers for Health Research (DZG) are dedicated to researching the major widespread diseases, which are often interlinked. Comorbidities and the side effects of therapies can have an impact on various organ systems, which requires a holistic understanding of disease interrelationships. In order to meet this need, the DZG have developed a common basic data set for clinical studies. This enables the uniform and structured recording of clinical data and its analysis beyond disease boundaries.

Compare patient cohorts and recognise correlations

Harmonised data collection across different clinical pictures provides valuable insights into common risk factors, disease mechanisms and therapeutic approaches. Particularly in the case of diseases with similar characteristics, such as cardiovascular diseases and metabolic diseases, the basic data set allows patient cohorts to be compared in a more targeted manner and links to be recognised that would otherwise remain undetected. One example: analysing inflammatory markers in patients with diabetes and heart failure could provide new insights into how chronic inflammation influences the development of both diseases - and possibly enable new, joint therapies.

The basic data set comprises 28 mandatory items that form the basis for identifying and analysing patient collectives across the DZG. In addition, an extended data set with 100 further items is available, which are relevant for cross-indication scientific questions. Disease-specific items are additionally recorded in the respective centres in order to support specific research requirements.

Conduct research across indications - understanding disease mechanisms

The DZG basic dataset helps researchers to identify cohorts of patients across the various research centres and creates new opportunities for collaboration and data exchange. Researchers can request and use data on this basis to answer specific scientific questions. The expanded dataset also makes it possible to harmonise multidisciplinary studies and thus gain new insights into disease mechanisms that exceed the scope of individual diseases. The unified datasets promote collaboration between the DZGs, as they facilitate data sharing and support cooperation.

‘The DZG basic dataset represents an important step towards more effective and interconnected health research. By standardising data across disease boundaries, we enable researchers to discover new correlations and better understand the mechanisms of action of diseases. This not only improves the quality of the data, but also creates a solid basis for innovative, joint research projects,’ says Prof. Martin Martin Hrabě de Angelis, Director of the German Centre for Diabetes Research and current spokesperson for the German Centres for Health Research.

The first version of the basic dataset was published in 2022 and has been mandatory in all DZG-funded studies since 2024. It can be viewed by the interested research community in the MDM-Portal.

Contact:

Spokesperson AG Research-IT

Jori Kern, German Consortium for Translational Cancer Research

Dr. Raphael Majeed, German Center for Lung Research

 

Website of the Research IT Working Group

Dysfunctions of the tiny cell processes (primary cilia*) of the pancreatic beta cells could be a cause of type 2 diabetes. Little is known about the structure and function of these cilia. An international research team led by DZD researchers from the Paul Langerhans Institute Dresden (PLID) at Helmholtz Munich of the Faculty of Medicine of the Technical University of Dresden has used various new imaging techniques to visualize the primary cilia in their natural environment. Their investigations not only provide detailed insights into the structure of these cilia, but also show their connection to the nervous system. The results have now been published in Nature Communications.

The beta cells of the pancreas are responsible for releasing the hormone insulin, which is vital for the absorption of glucose from the bloodstream. Various factors can impair the ability of these cells to produce insulin. This can lead to the development of type 2 diabetes (T2D). Current studies indicate that dysfunctions of the primary cilia of the beta cells may also be a cause of T2D.

Most cells in our body have immobile primary cilia. These small projections are stabilized by a kind of scaffold made of tubular protein rods, the microtubules. The cilia help the cells to receive and transmit signals from the outside. An international team from PLID, a partner of the German Center for Diabetes Research (DZD), the Human Technopole in Italy, the Janelia Research Campus and Yale University in the USA, investigated the structure of the primary cilia of beta cells as well as their function. Under the direction of Dr. Andreas Müller, scientist in the Department of Molecular Diabetology at the PLID (Director: Prof. Michele Solimena) and first author of the study, imaging techniques such as volume electron microscopy (vEM), 3D segmentation and ultrastructure expansion microscopy (U-ExM) were used to visualize the three-dimensional shape of the primary cilia of beta cells in their natural environment.

Special design of the skeletal structure

The primary cilia observed in this study originated from both animal and human beta cells. The researchers investigated how the skeletal structure (axoneme) formed from microtubules is organized. They discovered structural features of stabilizing cilia with microtubules that ended at different distances within the cilium. This was demonstrated for the first time in the cilia of beta cells.

Role in signal transmission between beta cells and other islet cells

The researchers also examined how the cilia interact with neighboring cells in order to draw conclusions about their signaling functions. They found that the primary cilia exchange information closely with surrounding cells and their cilia and play an important role in the signal transmission and networking of beta cells with other islet cells. They form synapse-like structures that pinch neighboring cells.

Interactions with cells of the nervous tissue

Further analyses of the image data indicated that the primary cilia of the beta cells also interact with cells of the nervous tissue. This could indicate a role in neuronal signal transmission.

“The structural data of this study show the importance of the primary cilia of beta cells as important junctions for islet cell function,” Müller summarizes the results.

In order to better understand how the primary cilia are involved in T2D pathogenesis, the researchers want to further investigate the mechanisms and pathways. This research is supported by the DZD Young Talent Program.

*Primary cilia
Primary cilia are small, sensory structures that occur in many cell types. They act like small antennas that perceive signals from the environment and transmit them to the inside of the cell.  These small projections are stabilized by a kind of scaffold made of tubular protein rods, the microtubules. In the beta cells of the pancreas, primary cilia play a role in communication between cells and are associated with diabetes.

Original publication: Structure, interaction, and nervous connectivity of beta cell primary cilia. Müller, A., Klena, N., Pang, S. et al. Nat Commun 15, 9168 (2024).

Source: DZD